Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Condition:   Breast Cancer Intervention:   Drug: Neratinib + endocrine therapy Sponsor:   SOLTI Breast Cancer Research Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials